305 related articles for article (PubMed ID: 33509126)
21. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors.
Mäkinen N; Zhou M; Zhang Z; Kasai Y; Perez E; Kim GE; Thirlwell C; Nakakura E; Meyerson M
Genome Med; 2022 Aug; 14(1):82. PubMed ID: 35922826
[TBL] [Abstract][Full Text] [Related]
22. Genomic landscape of pancreatic neuroendocrine tumors.
Gebauer N; Schmidt-Werthern C; Bernard V; Feller AC; Keck T; Begum N; Rades D; Lehnert H; Brabant G; Thorns C
World J Gastroenterol; 2014 Dec; 20(46):17498-506. PubMed ID: 25516664
[TBL] [Abstract][Full Text] [Related]
23. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
[TBL] [Abstract][Full Text] [Related]
24. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
[TBL] [Abstract][Full Text] [Related]
25. The Lymph Node Ratio Optimizes Staging in Patients with Small Intestinal Neuroendocrine Tumors.
Wu L; Chen F; Chen S; Wang L
Neuroendocrinology; 2018; 107(3):209-217. PubMed ID: 29920478
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological characterization of SMAD4-mutated intestinal adenocarcinomas: A case-control study.
Liao X; Hao Y; Zhang X; Ward S; Houldsworth J; Polydorides AD; Harpaz N
PLoS One; 2019; 14(2):e0212142. PubMed ID: 30730996
[TBL] [Abstract][Full Text] [Related]
27. Clinical Features of Multiple Endocrine Neoplasia Type 4: Novel Pathogenic Variant and Review of Published Cases.
Frederiksen A; Rossing M; Hermann P; Ejersted C; Thakker RV; Frost M
J Clin Endocrinol Metab; 2019 Sep; 104(9):3637-3646. PubMed ID: 30990521
[TBL] [Abstract][Full Text] [Related]
28. Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene.
Bläker H; von Herbay A; Penzel R; Gross S; Otto HF
Oncogene; 2002 Jan; 21(1):158-64. PubMed ID: 11791187
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
30. miRNA profiling of small intestinal neuroendocrine tumors defines novel molecular subtypes and identifies miR-375 as a biomarker of patient survival.
Arvidsson Y; Rehammar A; Bergström A; Andersson E; Altiparmak G; Swärd C; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2018 Aug; 31(8):1302-1317. PubMed ID: 29487354
[TBL] [Abstract][Full Text] [Related]
31. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Hofving T; Arvidsson Y; Almobarak B; Inge L; Pfragner R; Persson M; Stenman G; Kristiansson E; Johanson V; Nilsson O
Endocr Relat Cancer; 2018 Mar; 25(3):367-380. PubMed ID: 29444910
[TBL] [Abstract][Full Text] [Related]
32. Expression profiling of small intestinal neuroendocrine tumors identified pathways and gene networks linked to tumorigenesis and metastasis.
Wang Q; Yu C
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32496505
[TBL] [Abstract][Full Text] [Related]
33. Toward a Preoperative Classification of Lymph Node Metastases in Patients with Small Intestinal Neuroendocrine Tumors in the Era of Intestinal-Sparing Surgery.
Lardière-Deguelte S; de Mestier L; Appéré F; Vullierme MP; Zappa M; Hoeffel C; Noaves M; Brixi H; Hentic O; Ruszniewski P; Cadiot G; Panis Y; Kianmanesh R
Neuroendocrinology; 2016; 103(5):552-9. PubMed ID: 26445315
[TBL] [Abstract][Full Text] [Related]
34. Loss of SMAD4 function in small intestinal adenocarcinomas: comparison of genetic and immunohistochemical findings.
Bläker H; Aulmann S; Helmchen B; Otto HF; Rieker RJ; Penzel R
Pathol Res Pract; 2004; 200(1):1-7. PubMed ID: 15157044
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer.
Jia X; Shanmugam C; Paluri RK; Jhala NC; Behring MP; Katkoori VR; Sugandha SP; Bae S; Samuel T; Manne U
Oncotarget; 2017 Mar; 8(12):20198-20212. PubMed ID: 28423626
[TBL] [Abstract][Full Text] [Related]
36. Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.
Grabowski P; Schrader J; Wagner J; Hörsch D; Arnold R; Arnold CN; Georgieva I; Stein H; Zeitz M; Daniel PT; Sturm I
Clin Cancer Res; 2008 Nov; 14(22):7378-84. PubMed ID: 19010853
[TBL] [Abstract][Full Text] [Related]
37. CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors.
Barbareschi M; Roldo C; Zamboni G; Capelli P; Cavazza A; Macri E; Cangi MG; Chilosi M; Doglioni C
Am J Surg Pathol; 2004 Sep; 28(9):1169-76. PubMed ID: 15316316
[TBL] [Abstract][Full Text] [Related]
38. Chromosome 18 deletions are common events in classical midgut carcinoid tumors.
Löllgen RM; Hessman O; Szabo E; Westin G; Akerström G
Int J Cancer; 2001 Jun; 92(6):812-5. PubMed ID: 11351300
[TBL] [Abstract][Full Text] [Related]
39. [Genetic profile of gastroenteropancreatic neuroendocrine tumors].
Cabezas Agrícola JM
Endocrinol Nutr; 2009 Apr; 56 Suppl 2():16-9. PubMed ID: 19627765
[TBL] [Abstract][Full Text] [Related]
40. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer.
Aitchison AA; Veerakumarasivam A; Vias M; Kumar R; Hamdy FC; Neal DE; Mills IG
Prostate; 2008 May; 68(6):661-74. PubMed ID: 18213629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
